Abstract
TB is the 9th leading cause of death worldwide above HIV/AIDS. Tuberculosis (TB) management remains challenging due to the emergence of drug-resistant tuberculosis such as MDR-TB and XDR-TB. To improvise therapeutic results for MDR/XDR-TB, 89 nations had started utilizing bedaquiline and 54 had utilized delamanid by June 2017. Unfortunately, cardiac arrhythmia was found to be the most serious side effect associated with the both drugs restricting their use for the management of MDR- and XDR-TB. The current review discussed the clinically trialed and approved drug for the treatment of XDR-TB, recently reported compounds against XDR-TB, their synthesis and activity spectrum. This information could be helpful to the medicinal chemist in synthesizing the best XDR-TB inhibitors free from resistance and toxicity.
Similar content being viewed by others
REFERENCES
Global Tuberculosis Report 2017. www.who.int/tb/publications/global_report/MainText_13Nov2017.pdf?ua=1.
Shah, N.S., Wright, A., Bai, G.H., Barrera, L., Boulahbal, F., Martín-Casabona, N., Drobniewski, F., Gilpin, C., Havelková, M., Lepe, R., and Lumb, R., Emerging Infect. Dis., 2007, vol. 13, p. 380.
Migliori, G.B., Besozzi, G., and Girardi, E., Eur. Respir. J., 2007, vol. 30, p. 623.
Diacon, A.H., Donald, P.R., Pym, A., Grobusch, M., Patientia, R.F., Mahanyele, R., Bantubani, N., Narasimooloo, R., De Marez, T., Van Heeswijk, R., and Lounis, N., Antimicrob. Agents Chemother., 2012, vol. 56, p. 3271.
Carole, D., Sonaya, S., and Kwonjune, J., N. Engl. J. Med., 2008, vol. 359, p. 567.
Centers for Disease Control and Prevention. Revised definition of extensively drug resistant tuberculosis, Morb. Mortal. Wkly. Rep., 2006, vol. 55, p. 1176.
Datta, B.S., Hassan, G., Kadri, S.M., Qureshi, W., Kamili, M.A., Singh, H., Manzoor, A., Wani, M.A., Din, S., and Thakur, N., J. Infect. Dev. Countries, 2009, vol. 4, p. 19.
Raviglione, M.C. and Smith, I.M., N. Engl. J. Med., 2007, vol. 356, p. 656.
Rajasekaran, S., Chandrasekar, C., Mahilmaran, A., Kanakaraj, K., Karthikeyan, D.S., and Suriakumar, J., J. Indian Med. Assoc., 2009, vol. 107, p. 281.
Myneedu, V.P., Visalakshi, P., Verma, A.K., Behera, D., and Bhalla, M., Indian J. Tuberc., 2011, vol. 58, p. 54.
Grobusch, M.P., Curr. Opin. Pulm. Med., 2010, vol. 16, p. 180.
Matteelli, A., Migliori, G.B., Cirillo, D., Centis, R., Girard, E., and Raviglione, M., Expert Rev. Anti-Infect. Ther., 2007, vol. 5, p. 857.
Migliori, G.B., Richardson, M.D., Sotgiu, G., and Lange, C., Clin. Chest Med., 2009, vol. 30, p. 637.
Sotgiu, G., Ferrara, G., Matteelli, A., Richardson, M.D., Centis, R., Ruesch-Gerdes, S., Toungoussova, O., Zellweger, J.P., Spanevello, A., Cirillo, D., and Lange, C., Eur. Respir. J., 2009, vol. 33, p. 871.
Mondal, R. and Jain, A., Emerging Infect. Dis., 2007, vol. 13, p. 1429.
James, P., Christopher, D.J., Balamugesh, T., and Gupta, R., Int. J. Tuberc. Lung Dis., 2009, vol. 13, p. 795.
Keshavjee, S., Gelmanova, I.Y., Farmer, P.E., Mishustin, S.P., Strelis, A.K., Andreev, Y.G., Pasechnikov, A.D., Atwood, S., Mukherjee, J.S., Rich, M.L., and Furin, J.J., Lancet, 2008, vol. 372, p. 1403.
Kwon, Y.S., Kim, Y.H., Suh, G.Y., Chung, M.P., Kim, H., Kwon, O.J., Choi, Y.S., Kim, K., Kim, J., Shim, Y.M., and Koh, W.J., Clin. Infect. Dis., 2008, vol. 47, p. 496.
Mitnick, C.D., Shin, S.S., Seung, K.J., Rich, M.L., Atwood, S.S., Furin, J.J., Fitzmaurice, G.M., Alcantara Viru, F.A., Appleton, S.C., Bayona, J.N., and Bonilla, C.A., N. Engl. J. Med., 2008, vol. 359, p. 563.
Shah, N.S., Pratt, R., Armstrong, L., Robison, V., Castro, K.G., and Cegielski, J.P., JAMA, 2008, vol. 300, p. 2153.
Diacon, A.H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., and Venter, A., N. Engl. J. Med., 2009, vol. 360, p. 2397.
Stover, C.K., Warrener, P., VanDevanter, D.R., Sherman, D.R., Arain, T.M., Langhorne, M.H., Anderson, S.W., Towell, J.A., Yuan, Y., McMurray, D.N., and Kreiswirth, B.N., Nature, 2000, vol. 405, p. 962.
Patel, H.M., Noolvi, M.N., Sethi, N.S., Gadad, A.K., and Cameotra, S.S., Arab. J. Chem., 2017, vol. 10, p. S996.
Chaudhari, K.S., Patel, H.M., and Surana, S.J., Ind. J. Tuberc., 2017, vol. 64, p. 119.
Chaudhari, K., Surana, S., Jain, P., and Patel, H.M., Eur. J. Med. Chem., 2016, vol. 124, p. 160.
Shaikh, M.S., Palkar, M.B., Patel, H.M., Rane, R.A., Alwan, W.S., Shaikh, M.M., Shaikh, I.M., Hampannavar, G.A., and Karpoormath, R., RSC Adv., 2014, vol. 4, p. 62308.
Sensi, P., Rev. Infect. Dis., 1983, vol. 5, p. S402.
Koul, A., Vranckx, L., and Dendouga, N., J. Biol. Chem., 2008, vol. 283, p. 25273.
Andries, K., Verhasselt, P., Guillemont, J., Gohlmann, H.W., Neefs, J.M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., and Williams, P., Science, 2005, vol. 307, p. 223.
Mahajan, R., Int. J. Appl. Basic Med. Res., 2013, vol. 3, p. 1.
Kakkar, A.K. and Dahiya, N., Tuberculosis, 2014, vol. 94, p. 357.
Fox, G.J. and Menzies, D., Infect. Dis. Ther., 2013, vol. 2, p. 123.
Guglielmetti, L., Jaspard, M., Le Du, D., Lachatre, M., Marigot-Outtandy, D., Bernard, C., Veziris, N., Rober, J., Yazdanpanah, Y., Caumes, E., and Frechet-Jachym, M., Eur. Respir. J., 2016, vol. 49, 1601799.
Sotgiu, G., Pontali, E., Centis, R., D’Ambrosio, L., and Migliori, G.B., Expert Rev. Anti-Infect. Ther., 2015, vol. 13, p. 305.
Harausz, E., Cox, H., Rich, M., Mitnick, C.D., Zimetbaum, P., and Furin, J., Int. J. Tuberc. Lung Dis., 2015, vol. 19, p. 385.
Global tuberculosis control: WHO report 2010 Geneva: World Health Organization, 2010 (WHO/HTM/TB/2010.7).
Global tuberculosis control: WHO report 2012. Geneva: World Health Organization, 2012 (WHO/HTM/TB/2012.6).
Diacon, A.H., Pym, A., Grobusch, M.P., de Los, Rios., Gotuzzo, E., Vasilyeva, I., Leimane, V., Andries, K., Bakare, N., De Marez, T., and Haxaire-Theeuwes, M., N. Engl. J. Med., 2014, vol. 371, p. 723.
Cox, E. and Laessig, K., N. Engl. J. Med., 2014, vol. 371, p. 689.
STREAM stage 2 clinical study enrols patients in first trial to include Bedaquiline to test shortened MDR-TB treatment regimens, International Union against Tuberculosis and Lung Disease 2016. www.theunion.org.
Worley, M.V. and Estrada, S.J., Pharmacotherapy, 2014, vol. 34, p. 1187.
Andries, K., Villellas, C., Coeck, N., Thys, K., Gevers, T., Vranckx, L., Lounis, N., de Jong, B.C., and Koul, A., PLoS One, 2014, vol. 9, 102135.
Protopopova, M., Bogatcheva, E., Nikonenko, B., Hundert, S., Einck, L., and Nacy, C.A., Med. Chem., 2007, vol. 3, p. 301.
Diacon, A.H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., and Venter, A., N. Engl. J. Med., 2009, vol. 360, p. 2397.
Deltybadelamanid summary of the European public assessment report (EPAR) for Deltyba, European Medicines Agency 2013. www.ema.europa.eu.
Deltybadelamanid summary of the European public assessment report (EPAR) for Deltyba, European Medicines Agency 2013. www.ema.europa.eu.
Gler, M.T., Skripconoka, V., Sanchez-Garavito, E., Xiao, H., Cabrera-Rivero, J.L., Vargas-Vasquez, D.E., Gao, M., Awad, M., Park, S.K., Shim, T.S., and Suh, G.Y., N. Engl. J. Med., 2012, vol. 366, p. 2151.
Diacon, A.H., Dawson, R., Hanekom, M., Narunsky, K., Venter, A., Hittel, N., Geiter, L.J., Wells, C.D., Paccaly, A.J., and Donald, P.R., Int. J. Tuberc. Lung Dis., 2011, vol. 15, p. 949.
Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y., and Komatsu, M., PLoS Med., 2006, vol. 3, p. e466.
Saliu, O.Y., Crismale, C., Schwander, S.K., and Wallis, R.S., J. Antimicrob. Chemother., 2007, vol. 60, p. 994.
Zhang, Q., Liu, Y., Tang, S., Sha, W., and Xiao, H., Cell Biochem. Biophys., 2013, vol. 67, p. 957.
Otsuka Pharmaceutical. Safety and efficacy of delamanid for 6 months in patients with multidrug resistant tuberculosis [NCT01424670]. http://clinicaltrials.gov/ct2/show/NCT01424670?term=delamanid&rank=3. Accessed May 14, 2014.
Otsuka Pharmaceutical. Pharmacokinetic and safety trial to determine the appropriate dose for pediatric patients with multidrug resistant tuberculosis [NCT01856634]. http://clinicaltrials.gov/ct2/show/NCT01856634? term=NCT01856634& rank=1. Accessed May 14, 2014.
Otsuka Pharmaceutical. A 6-month safety, efficacy and pharmacokinetic trial of delamanid in pediatric patients with multidrug resistant tuberculosis [NCT01859923]. http://clinicaltrials.gov/ct2/show/NCT01859923?term =NCT01859923& rank=1. Accessed May 14, 2014.
Blair, H.A. and Scott, L.J., Drugs, 2015, vol. 75, p. 91.
Brickner, S.J., Hutchinson, D.K., Barbachyn, M.R., Manninen, P.R., Ulanowicz, D.A., Garmon, S.A., Grega, K.C., Hendges, S.K., Toops, D.S., Ford, C.W., and Zurenko, G.E., J. Med. Chem., 1996, vol. 39, p. 673.
Ashtekar, D.R., Costa-Perira, R., Nagrajan, K., Vishvanathan, N., Bhatt, A.D., and Rittel, W., Antimicrob. Agents Chemother., 1993, vol. 37, p. 183.
Zhang, Y., Post-Martens, K., and Denkin, S., Drug Discovery Today, 2006, vol. 11, p. 21.
Dietze, R., Hadad, D.J., McGee, B., Molino, L.P., Maciel, E.L., Peloquin, C.A., Johnson, D.F., Debanne, S.M., Eisenach, K., Boom, W.H., and Palaci, M., Am. J. Respir. Crit. Care Med., 2008, vol. 178, p. 1180.
Fortun, J., Martin-Davila, P., Navas, E., Perez-Elias, M.J., Cobo, J., Tato, M., De la Pedrosa, E.G., Gomez-Mampaso, E., and Moreno, S., J. Antimicrob. Chemother., 2005, vol. 56, p. 180.
Park, I.N., Hong, S.B., Oh, Y.M., Kim, M.N., Lim, C.M., Lee, S.D., Koh, Y., Kim, W.S., Kim, D.S., Kim, W.D., and Shim, T.S., J. Antimicrob. Chemother., 2006, vol. 58, p. 701.
Schecter, G.F., Scott, C., True, L., Raftery, A., Flood, J., and Mase, S., Clin. Infect. Dis., 2010, vol. 50, p. 49.
Nix-TB: Testing a new potential treatment for XDR-TB. www.tballiance.org/downloads/NixTB/NixTB_factsheet.pdf.
Mahajan, N.S. and Dhawale, S.C., Eur. J. Med. Chem., 2015, vol. 102, p. 243.
Roh, J., Karabanovich, G., Vlckova, H., Carazo, A., Nemecek, J., Sychra, P., Valaskova, L., Pavlis, O., Stolarikova, J., Klimesova, V., and Vavrova, K., Bioorg. Med. Chem., 2017, vol. 25, p. 5468.
Azzali, E., Machado, D., Kaushik, A., Vacondio, F., Flisi, S., Cabassi, C.S., Lamichhane, G., Viveiros, M., Costantino, G., and Pieroni, M., J. Med. Chem., 2017, vol. 60, p. 7108.
Stec, J., Onajole, O.K., Lun, S., Guo, H., Merenbloom, B., Vistoli, G., Bishai, W.R., and Kozikowski, A.P., J. Med. Chem., 2016, vol. 59, p. 6232.
Mundhe, D., Chandewar, A.V., and Shiradkar, M.R., Chem. Sin., 2011, vol. 2, p. 137.
Hemal, M.S., Popatbhai, K.P., Mahesh, T.C., Ashish, K.P., Dharmraj, N., and Pathik, S.B., Int. J. Org. Chem., 2016, vol. 6, p. 157.
Lu, W., Baig, I.A., Sun, H.J., Cui, C.J., Guo, R., Jung, I.P., Wang, D., Dong, M., Yoon, M.Y., and Wang, J.G., Eur. J. Med. Chem., 2015, vol. 94, p. 298.
Pan, L., Jiang, Y., Liu, Z., Liu, X.H., Liu, Z., Wang, G., Li, Z.M., and Wang, D., Eur. J. Med. Chem., 2012, vol. 50, p. 18.
Pieroni, M., Wan, B., Cho, S., Franzblau, S.G., and Costantino, G., Eur. J. Med. Chem., 2014, vol. 72, p. 26.
Pieroni, M., Machado, D., Azzali, E., Costa, S.S., Couto, I., Costantino, C., and Viveiros, M., J. Med. Chem., 2015, vol. 8, p. 5842.
ACKNOWLEDGMENTS
The authors would like to thank “Indian Council of Medical Research (ICMR)-New Delhi, Govt. of India” (Grant no. 2018-2953) for funding the Adhoc Research Grant.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
CONFLICT OF INTEREST
Authors have no conflict of interest.
AUTHORS CONTRIBUTION
Dr. Harun M. Patel contributed in the study design and manuscript writing, Dr. Rahul Pawara for data collection, Dr. Iqrar Ansari and Dr. Harsha Jadhav contributed for manuscript writing. Dr. Anand Mundada and Dr. S. J. Surana contributed for data analysis.
Rights and permissions
About this article
Cite this article
Patel, H., Ahmad, I., Jadhav, H. et al. Extensively Drug-resistant Tuberculosis (XDR-TB)-inhibitors to Overcome the Scourge of Drug-resistant Tuberculosis: a Perspective. rev. and adv. in chem. 10, 112–139 (2020). https://doi.org/10.1134/S2079978020030048
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S2079978020030048